Market closed
iRadimed/$IRMD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About iRadimed
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Ticker
$IRMD
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
148
Website
iRadimed Metrics
BasicAdvanced
$707M
Market cap
38.23
P/E ratio
$1.46
EPS
0.81
Beta
$0.93
Dividend rate
1.07%
Dividend yield
Price and volume
Market cap
$707M
Beta
0.81
52-week high
$55.42
52-week low
$39.24
Average daily volume
33K
Dividend rate
$0.93
Financial strength
Current ratio
9.213
Quick ratio
6.415
Long term debt to equity
0.003
Total debt to equity
0.003
Dividend payout ratio (TTM)
63.22%
Management effectiveness
Return on assets (TTM)
14.67%
Return on equity (TTM)
23.58%
Valuation
Price to earnings (TTM)
38.234
Price to revenue (TTM)
9.906
Price to book
8.48
Price to tangible book (TTM)
8.78
Price to free cash flow (TTM)
41.171
Dividend yield (TTM)
1.67%
Forward dividend yield
1.07%
Growth
Revenue change (TTM)
13.23%
Earnings per share change (TTM)
13.16%
3-year revenue growth (CAGR)
22.82%
3-year earnings per share growth (CAGR)
44.88%
What the Analysts think about iRadimed
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for iRadimed stock.
iRadimed Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
iRadimed Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
iRadimed News
AllArticlesVideos
IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024
GlobeNewsWire·4 days ago
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 week ago
IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closed
Upcoming events
Nov
15
iRadimed
Dividend·Ex-dividend
Nov
25
iRadimed
Dividend·Payment
$0.15
Per share
FAQs
What’s the current market cap for iRadimed stock?
iRadimed (IRMD) has a market cap of $707M as of November 08, 2024.
What is the P/E ratio for iRadimed stock?
The price to earnings (P/E) ratio for iRadimed (IRMD) stock is 38.23 as of November 08, 2024.
Does iRadimed stock pay dividends?
Yes, the iRadimed (IRMD) stock pays dividends to shareholders. As of November 08, 2024, the dividend rate is $0.93 and the yield is 1.07%. iRadimed has a payout ratio of 63.22% on a trailing twelve-month basis.
When is the next iRadimed dividend payment date?
The next iRadimed (IRMD) dividend payment is scheduled for November 25, 2024.
What is the beta indicator for iRadimed?
iRadimed (IRMD) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.